SELLAS Life Sciences Group, Inc (SLS)

Etorro trading 970x250

About SELLAS Life Sciences Group, Inc

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York. Address: Times Square Tower, New York, NY, United States, 10036

SELLAS Life Sciences Group, Inc News and around…

Latest news about SELLAS Life Sciences Group, Inc (SLS) common stock and company :

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
19 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to tackle the biggest pre-market stock movers for this morning as we get ready for trading hours to start on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
12 May, 2022 Yahoo! Finance

- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Million Milestone Payment Received in May 2022 Add to Cash Balance of $14.3 Million as of March 31, 2022 - NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapie

Stocks That Hit 52-Week Lows On Wednesday
11 May, 2022 FinancialContent

On Wednesday, 807 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Amazon.com ...

SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
26 Apr, 2022 Yahoo! Finance

Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML)NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company has launched a Pre-Approval Access/Expanded Access Program (“EAP”) with SELLAS’

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
14 Apr, 2022 FinancialContent

Upgrades For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, ...

SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
11 Apr, 2022 Yahoo! Finance

- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first acute myeloid leukemia (AML) patient has enrolled in the fifth dose lev

Week In Review: Harbour BioMed Signs $350 Million Out-license Deal For Bispecific With AstraZeneca
09 Apr, 2022 FinancialContent

Harbour BioMed out-licensed global rights for a pre-clinical bispecific candidate to AstraZeneca in a $350 million agreement. Harbour BioMed will receive $25 million upfront and as much as $325 million in milestones, plus royalties.

Stocks That Hit 52-Week Lows On Friday
08 Apr, 2022 FinancialContent

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week ...

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
06 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Iovance Plans to File For ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
06 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! Another day of trading lies ahead and we're starting it off with the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. 10 Stocks Are Issuing Sell Signals Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
06 Apr, 2022 Yahoo! Finance

SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that an Investigational New Drug (“IND”) application to initiate the first clinical trial in China for 3D189, also known as SELLAS’ galinpepimut-S (GPS), has b

GenFleet Out-Licenses CDK9 Inhibitor to Sellas in $150 Million Deal
06 Apr, 2022 FinancialContent

Shanghai GenFleet Therapeutics out-licensed global rights (ex-Greater China) for a small molecule cyclin-dependent kinase 9 (CDK9) inhibitor to New York’s Sellas Life Sciences in a $150 million deal. GFH009, currently in Phase I trials in the US and China, has a unique mechanism of action that leads to lower toxicity and more potent efficacy, according to GenFleet’s read of the initial pharmacokinetic data in the Phase I trial. In 2014, Sellas was formed to develop an inhibitor of the WT1 protein, which is present in many cancers. Sellas in-licensed the drug from Memorial Sloan Kettering Hospital. More details.... Stock Symbol: (NSDQ: SLS) Share this with colleagues:  

SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
05 Apr, 2022 Yahoo! Finance

– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial Officer – – Completed Enrollment in Phase 1/2 Study of Galinpepimut-S (GPS) in Combination with Merck’s KEYTRUDA® – – IND Application in China for Phase I Study of GPS Approved by China’s NMPA – – Shareholder Update Call on Wednesday, April 6th at 8:30 a.m. Eastern Time – NEW YORK, April 05, 2022 (GLOBE NEWSW

55 Biggest Movers From Friday
04 Apr, 2022 FinancialContent

Gainers Takung Art Co., Ltd. (NASDAQ: TKAT) surged 61.8% to close at $3.64 on Friday. Chicken Soup for the Soul Entertainment, ...

Mid-Afternoon Market Update: Nasdaq Turns Lower; Chicken Soup for the Soul Entertainment Shares Spike Higher
01 Apr, 2022 FinancialContent

U.S. stocks pared gains, with the Nasdaq Composite turning lower toward the end of trading on Friday. The Dow traded up 0.16% to ...

Mid-Day Market Update: Gold Drops Over 1%; Manning & Napier Shares Jump
01 Apr, 2022 FinancialContent

U.S. stocks traded slightly higher midway through trading following the release of non-farm payroll data for March. The Dow traded up ...

38 Stocks Moving In Friday's Mid-Day Session
01 Apr, 2022 FinancialContent

Gainers Manning & Napier, Inc. (NYSE: MN) jumped 40.7% to $12.82 after the company reported it will be acquired by Callodine ...

Mid-Morning Market Update: Markets Higher; US Economy Adds 431,000 Jobs In March
01 Apr, 2022 FinancialContent

U.S. stocks opened higher this morning following the release of non-farm payroll data for March. The Dow traded up 0.17% to 34,735.64 ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
01 Apr, 2022 FinancialContent

Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market ...

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
01 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Reata Completes Regulatory ...

SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor
01 Apr, 2022 FinancialContent

GenFleet Therapeuticshas granted GFH009 rightstoSELLAS Life Sciences Group Inc(NASDAQ: SLS) across all ...

SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
01 Apr, 2022 Yahoo! Finance

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 4,629,630 shares of its common stock and accompanying warrants to purchase up to 4,629,630 shares of common stock at a combined public offering price of $5.

SELLAS Life Sciences Announces Proposed Underwritten Public Offering
31 Mar, 2022 Yahoo! Finance

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the securities in the offering will be sold by SELLAS. SVB Leerink and Cantor are ac

SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
31 Mar, 2022 Yahoo! Finance

- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset - - Completion of Ongoing Phase 1 Trial in the United States/China Expected by Q4 2022 in Relapsed and/or Refractory Hematologic Malignancies - - SELLAS Expects to Initiate Phase 1 Study in Pediatric Soft Tissue Sarcomas in Late 2022/Early 2023 - - SELLAS and GenFleet Expect to Initiate Multiple Phase 2 Trials in Hematological Malignancies and Solid Tumors in 2023 to Expedite CDK9 Inhibitor Development - NEW

SELLAS Life Sciences Group (NASDAQ:SLS) adds US$28m to market cap in the past 7 days, though investors from three years ago are still down 88%
21 Mar, 2022 Yahoo! Finance

SELLAS Life Sciences Group, Inc. ( NASDAQ:SLS ) shareholders will doubtless be very grateful to see the share price up...

SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer
14 Mar, 2022 Yahoo! Finance

Biopharmaceutical Veteran Brings More Than 25 Years of Experience to SELLASNEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today that the Company has appointed Robert Francomano as Chief Commercial Officer, effective immediately. Mr. Francomano brings significant and broad biopharmac

SELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation
28 Feb, 2022 Yahoo! Finance

– Marks an End to All Litigation Related to Activities of SELLAS’ Predecessor, Galena Biopharma –NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on February 24, 2022 the United States District Court for the District of New Jersey issued final approval of the settlement of t

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
01 Feb, 2022 Yahoo! Finance

Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15 Evaluable Patients Expected in Mid-2022 with Final Data for up to 17 Patients in Q4 2022 NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced t

SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China
28 Jan, 2022 FinancialContent
12 Health Care Stocks Moving In Thursday's After-Market Session
27 Jan, 2022 FinancialContent

Gainers Avidity Biosciences (NASDAQ:RNA) shares increased by 42.2% to $20.2 during Thursday's after-market session. The market value ...

SELLAS Life Sciences Group, Inc (SLS) is a NASDAQ Common Stock listed in , ,

970x250